Tu banner alternativo

Fenleuton

In Fenleuton's article we will explore a fascinating topic that has captured the interest of people of all ages and backgrounds. Whether you are looking for information about Fenleuton or simply want to deepen your knowledge, this article will give you a detailed and comprehensive overview of the topic. From its origin to the latest research and trends, I will take you on a journey through the most important and fascinating aspects of Fenleuton. Get ready to immerse yourself in a world of discovery and learning as we explore this exciting topic together.

Tu banner alternativo
Fenleuton
Clinical data
Trade namesLofrin
ATC code
  • none
Identifiers
  • 1-{4--3-butyn-2-yl}-1-hydroxyurea
CAS Number
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H15FN2O3
Molar mass314.316 g·mol−1
3D model (JSmol)
  • CC(C#Cc1cccc(c1)Oc2ccc(cc2)F)N(C(=O)N)O
  • InChI=InChI=1S/C17H15FN2O3/c1-12(20(22)17(19)21)5-6-13-3-2-4-16(11-13)23-15-9-7-14(18)8-10-15/h2-4,7-12,22H,1H3,(H2,19,21)
  • Key:MWXPQCKCKPYBDR-UHFFFAOYSA-N[1]

Fenleuton (trade name Lofrin) is a drug that acts as a 5-lipoxygenase inhibitor and inhibits leukotriene (LTB4, LTC4, LTD4, and LTE4) formation. It has been studied for potential use in veterinary medicine to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD) in horses.[2]

References

  1. ^ "1-{4-[3-(4-Fluorophenoxy)phenyl]-3-butyn-2-yl}-1-hydroxyurea". chemspider.com. Retrieved 24 December 2015.
  2. ^ Marr KA, Lees P, Page CP, Cunningham FM (1998). "Effect of the 5-lipoxygenase inhibitor, fenleuton, on antigen-induced neutrophil accumulation and lung function changes in horses with chronic obstructive pulmonary disease". J Vet Pharmacol Ther. 21 (3): 241–246. doi:10.1046/j.1365-2885.1998.00127.x. PMID 9673966.


Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia